



Curriculum Vitae

Prof. Dr. med. Karsten-Henrich Weylandt, D.Phil.

Facharzt für Innere Medizin, Schwerpunktbezeichnung Gastroenterologie

Aktuelle Position

Chefarzt der Medizinische Klinik B für Gastroenterologie, Hepatologie, Diabetes, Rheumatologie
Onkologie, Hämatologie, Palliativmedizin

Ruppiner Kliniken GmbH
Hochschulklinikum der Medizinischen Hochschule Brandenburg
Fehrbelliner Straße 38
16816 Neuruppin

T: +49-3391-393210
F: +49-3391-393202
E: k.weylandt@ruppiner-kliniken.de

Medical and Scientific University Education

04/1993–09/1996	Preclinical Training, Heidelberg University.
04/1995–10/1995	Research Training, Massachusetts General Hospital and Harvard Medical School Boston.
10/1996–03/1997	Clinical Training, King's College London.
04/1997–09/1997	Clinical Training Free University Berlin.
10/1997–03/2001	PhD in Clinical Biochemistry, Oxford University.
2001	Clinical Training in Internal Medicine at the Kantonsspital Basel.
04/2001–04/2002	Clinical Training Free University Berlin.

Postgraduate Training

05/2002–09/2009	Residency and Fellowship Program in Internal Medicine at the Charité.
10/2009–09/2011	Research Fellow & Instructor at the Massachusetts General Hospital and Harvard Medical School, Boston.
10/2011–03/2017	Attending physician (Oberarzt) at the Charité.
Since 04/2017	Full Professor for Gastroenterology, Brandenburg Medical School, and Head of the Medizinische Klinik B (Gastroenterology, Hepatology, Diabetes, Rheumatology, Hematology, Oncology), Ruppiner Kliniken, Neuruppin, Brandenburg, Germany.

Degrees and Certification

2001 PhD in Clinical Biochemistry, Oxford University.

05/2002 MD, Heidelberg University.

05/2002 Approbation as Physician in Germany.

2009 Habilitation in Experimental Medicine, Charité University Medicine.

07/2009 Board Examination in Internal Medicine (Facharzt für Innere Medizin).

04/2016 Board Examination in Gastroenterology.

Awards

- Scholarships of the German National Scholarship Foundation (Studienstiftung des deutschen Volkes), the German Academic Exchange Service (DAAD) and (as part of the Marie-Curie Program) of the European Union.
-
- Werner-Creutzfeldt-Scholar of the German Society for Digestive and Metabolic Disease (DGVS) and Recipient of the MSD Oncology Research Award.
-

Publications

1996

1. Weylandt, K. H., J. X. Kang, and A. Leaf. 1996. Polyunsaturated fatty acids exert antiarrhythmic actions as free acids rather than in phospholipids. *Lipids* **31**: 977-982.
-

2001

1. Weylandt, K. H., M. A. Valverde, M. Nobles, S. Raguz, J. S. Amey, M. Diaz, C. Nastrucci, C. F. Higgins, and A. Sardini. 2001. Human CLC-3 is not the swelling-activated chloride channel involved in cell volume regulation. *J Biol Chem* **276**: 17461-17467.
-

2003

1. Sardini, A., J. S. Amey, K. H. Weylandt, M. Nobles, M. A. Valverde, and C. F. Higgins. 2003. Cell volume regulation and swelling-activated chloride channels. *Biochim Biophys Acta* **1618**: 153-162.
-

2005

1. Weylandt, K. H., and J. X. Kang. 2005. Rethinking lipid mediators. *Lancet* **366**: 618-620.
-

2006

1. Okkenhaug, H., K. H. Weylandt, D. Carmena, D. J. Wells, C. F. Higgins, and A. Sardini. 2006. The human CLC-4 protein, a member of the CLC chloride channel/transporter family, is localized to the endoplasmic reticulum by its N-terminus. *FASEB J* **20**: 2390-2392.
-

2007

1. Nowak, J., K. H. Weylandt, P. Habel, J. Wang, A. Dignass, J. N. Glickman, and J. X. Kang. 2007. Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. *Carcinogenesis* **28**: 1991-1995.
 2. Schmocker, C., K. H. Weylandt, L. Kahlke, J. Wang, H. Lobeck, G. Tiegs, T. Berg, and J. X. Kang. 2007. Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. *Hepatology* **45**: 864-869.
 3. Weylandt, K. H., J. X. Kang, B. Wiedenmann, and D. C. Baumgart. 2007. Lipoxins and resolvins in inflammatory bowel disease. *Inflamm Bowel Dis* **13**: 797-799.
 4. Weylandt, K. H., M. Nebrig, N. Jansen-Rosseck, J. S. Amey, D. Carmena, B. Wiedenmann, C. F. Higgins, and A. Sardini. 2007. CLC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment. *Mol Cancer Ther* **6**: 979-986.
-

2008

1. Kang, J. X., and K. H. Weylandt. 2008. Modulation of inflammatory cytokines by omega-3 fatty acids. *Subcell Biochem* **49**: 133-143.
2. Weylandt, K. H., A. Nadolny, L. Kahlke, T. Kohnke, C. Schmocker, J. Wang, G. Y. Lauwers, J. N. Glickman, and J. X. Kang. 2008. Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis. *Biochim Biophys Acta* **1782**: 634-641.

2009

1. Habbel, P., K. H. Weylandt, K. Lichopoj, J. Nowak, M. Purschke, J. D. Wang, C. W. He, D. C. Baumgart, and J. X. Kang. 2009. Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells. *World J Gastroenterol* **15**: 1079-1084.

2011

1. Bilal, S., O. Haworth, L. Wu, K. H. Weylandt, B. D. Levy, and J. X. Kang. 2011. Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. *Biochim Biophys Acta* **1812**: 1164-1169.
2. Gomolka, B., E. Siegert, K. Blossey, W. H. Schunck, M. Rothe, and K. H. Weylandt. 2011. Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. *Prostaglandins Other Lipid Mediat* **94**: 81-87.
3. Weylandt, K. H., L. F. Krause, B. Gomolka, C. Y. Chiu, S. Bilal, A. Nadolny, S. F. Waechter, A. Fischer, M. Rothe, and J. X. Kang. 2011. Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-alpha. *Carcinogenesis* **32**: 897-903.

2012

1. Chiu, C. Y., B. Gomolka, C. Dierkes, N. R. Huang, M. Schroeder, M. Purschke, D. Manstein, B. Dangi, and K. H. Weylandt. 2012. Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. *Inflamm Res* **61**: 967-976.
2. Weylandt, K. H., C. Y. Chiu, B. Gomolka, S. F. Waechter, and B. Wiedenmann. 2012. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. *Prostaglandins Other Lipid Mediat* **97**: 73-82.

2013

1. Calviello, G., H. M. Su, K. H. Weylandt, E. Fasano, S. Serini, and A. Cittadini. 2013. Experimental evidence of omega-3 polyunsaturated fatty acid modulation of inflammatory cytokines and bioactive lipid mediators: their potential role in inflammatory, neurodegenerative, and neoplastic diseases. *Biomed Res Int* **2013**: 743171.
2. Kohnke, T., B. Gomolka, S. Bilal, X. Zhou, Y. Sun, M. Rothe, D. C. Baumgart, and K. H. Weylandt. 2013. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. *Biomed Res Int* **2013**: 748160.

2014

1. Fischer, R., A. Konkel, H. Mehling, K. Blosser, A. Gapelyuk, N. Wessel, C. von Schacky, R. Dechend, D. N. Muller, M. Rothe, F. C. Luft, K. Weylandt, and W. H. Schunck. 2014. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. *J Lipid Res* **55**: 1150-1164.
-

2015

1. Keeren, K., D. Huang, C. Smyl, A. Fischer, M. Rothe, and K. H. Weylandt. 2015. Effect of Different Omega-6/Omega-3 Polyunsaturated Fatty Acid Ratios on the Formation of Monohydroxylated Fatty Acids in THP-1 Derived Macrophages. *Biology (Basel)* **4**: 314-326.
 2. Weylandt, K. H., Y. Q. Chen, K. Lim, H. M. Su, A. Cittadini, and G. Calviello. 2015. omega -3 PUFAs in the Prevention and Cure of Inflammatory, Degenerative, and Neoplastic Diseases 2014. *Biomed Res Int* **2015**: 695875.
 3. Weylandt, K. H., S. Serini, Y. Q. Chen, H. M. Su, K. Lim, A. Cittadini, and G. Calviello. 2015. Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence. *Biomed Res Int* **2015**: 143109.
-

2016

1. Schmocker, C., U. Kassner, S. Kiesler, M. Bismarck, M. Rothe, E. Steinhagen-Thiessen, and K. H. Weylandt. 2016. A lipidomic analysis approach in patients undergoing lipoprotein apheresis. *Atherosclerosis* **249**: 30-35.
 2. Weylandt, K. H. 2016. Docosapentaenoic acid derived metabolites and mediators - The new world of lipid mediator medicine in a nutshell. *Eur J Pharmacol* **785**: 108-115.
-

2017

1. Chiu, C. Y., C. Smyl, I. Dogan, M. Rothe, and K. H. Weylandt. 2017. Quantitative Profiling of Hydroxy Lipid Metabolites in Mouse Organs Reveals Distinct Lipidomic Profiles and Modifications Due to Elevated n-3 Fatty Acid Levels. *Biology (Basel)* **6**.
 2. Maasberg, S., B. Knappe-Drzikova, D. Vonderbeck, H. Jann, K. H. Weylandt, C. Grieser, A. Pascher, J. C. Schefold, M. Pavel, B. Wiedenmann, A. Sturm, and U. F. Pape. 2017. Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. *Neuroendocrinology* **104**: 11-25.
 3. Ostermann, A. I., M. Reutzel, N. Hartung, N. Franke, L. Kutzner, K. Schoenfeld, K. H. Weylandt, G. P. Eckert, and N. H. Schebb. 2017. A diet rich in omega-3 fatty acids enhances expression of soluble epoxide hydrolase in murine brain. *Prostaglandins Other Lipid Mediat* **133**: 79-87.
 4. Ostermann, A. I., P. Waindok, M. J. Schmidt, C. Y. Chiu, C. Smyl, N. Rohwer, K. H. Weylandt, and N. H. Schebb. 2017. Modulation of the endogenous omega-3 fatty acid and oxylipin profile in vivo-A comparison of the fat-1 transgenic mouse with C57BL/6 wildtype mice on an omega-3 fatty acid enriched diet. *PLoS One* **12**: e0184470.
 5. Schmocker, C., U. Kassner, A. I. Ostermann, S. Kiesler, E. Steinhagen-Thiessen, N. H. Schebb, and K. H. Weylandt. 2017. Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids. *Atheroscler Suppl* **30**: 193-199.
-

6. Siegert, E., F. Paul, M. Rothe, and K. H. Weylandt. 2017. The effect of omega-3 fatty acids on central nervous system remyelination in fat-1 mice. *BMC Neurosci* **18**: 19.

7. Swidsinski, A., Y. Dorffel, V. Loening-Baucke, C. Gille, O. Goktas, A. Reissauer, J. Neuhaus, K. H. Weylandt, A. Guschin, and M. Bock. 2017. Reduced Mass and Diversity of the Colonic Microbiome in Patients with Multiple Sclerosis and Their Improvement with Ketogenic Diet. *Front Microbiol* **8**: 1141.

2018

1. Blessin, U. B., A. Fischer, T. Schneider, V. Moos, T. Muller, K. H. Weylandt, and U. Pleyer. 2018. More than meets the eye. *Gut* **67**: 69.

2. Gottschall, H., C. Schmoeker, D. Hartmann, N. Rohwer, K. Rund, L. Kutzner, F. Nolte, A. I. Ostermann, N. H. Schebb, and K. H. Weylandt. 2018. Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue. *J Lipid Res*.

3. Schmoeker, C., I. W. Zhang, S. Kiesler, U. Kassner, A. I. Ostermann, E. Steinhagen-Thiessen, N. H. Schebb, and K. H. Weylandt. 2018. Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. *Int J Mol Sci* **19**.

4. Schunck, W. H., A. Konkel, R. Fischer, and K. H. Weylandt. 2018. Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. *Pharmacol Ther* **183**: 177-204.
